YOUR SEARCH FOR Text 257 RESULTS
101 of Total
Q4 2023 Incyte Corporation Earnings Conference Call | Incyte
Event Details Events Corporate Presentations Scientific Presentations Q4 2023 Incyte Corporation Earnings Conference Call Feb 13, 2024 at 8:00 AM EST
102 of Total
Q4 2024 Incyte Corporation Earnings Conference Call | Incyte
Event Details Events Corporate Presentations Scientific Presentations Q4 2024 Incyte Corporation Earnings Conference Call Feb 10, 2025 at 8:00 AM EST
103 of Total
Q4/YE 2022 Incyte Corporation Earnings Conference Call | Incyte
Event Details Events Corporate Presentations Scientific Presentations Q4/YE 2022 Incyte Corporation Earnings Conference Call Feb 7, 2023 at 8:00 AM
104 of Total
Wells Fargo Healthcare Conference | Incyte
Event Details Events Corporate Presentations Scientific Presentations Wells Fargo Healthcare Conference Sep 4, 2025 at 8:45 AM EDT Click here for
105 of Total
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the Eu
Press Release View all news Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of
106 of Total
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with
Press Release View all news Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
107 of Total
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Offi
Press Release View all news Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer September 22,
108 of Total
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in
Press Release View all news Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis
109 of Total
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Canc
Press Release View all news Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D
110 of Total
Incyte to Report Third Quarter Financial Results | Incyte
Press Release View all news Incyte to Report Third Quarter Financial Results October 8, 2025 at 8:00 AM EDT PDF Version WILMINGTON, Del. --(BUSINESS